Physician profile
Yousif Ahmad
NPI 1447716725
$205,044.84
in general payments reported to CMS, 2019-2025
15 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,124 · 2021: $3,303 · 2022: $1,372 · 2023: $56K · 2024: $23K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Travel and Lodging: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $77,487.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $46,800.00 |
| Travel and Lodging | $31,804.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,825.00 |
| Food and Beverage | $16,328.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $121,127.36 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $52,145.10 | 2021-2025 | General - Vascular Access, General - Balloons, General - Ct_ic |
| Edwards Lifesciences Corporation | $8,782.46 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $7,734.31 | 2024-2025 | Impella |
| Medtronic, INC. | $4,878.10 | 2021-2025 | Resolute Onyx, Corevalve Evolut R, Onyx Frontier |
| Cardiovascular Systems INC. | $4,357.55 | 2022-2023 | Diamondback Coronary |
| Penumbra, INC. | $4,219.51 | 2024 | Indigo System |
| Ancora Heart, INC. | $379.31 | 2025 | Accucinch |
| Abbott Laboratories | $345.22 | 2023-2025 | Triclip, Diamondback Coronary, Portico |
| Philips North America LLC | $324.81 | 2021 | |
| Teleflex LLC | $310.62 | 2022-2025 | Guideliner, Vsi, Trapliner |
| Opsens INC. | $196.02 | 2022 | |
| Amgen INC. | $123.96 | 2021 | |
| Biotronik INC. | $108.85 | 2021 | |
| W. L. Gore & Associates, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousif Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.